MENLO PARK, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced plans to present at the Stifel 2025 Virtual Ophthalmology Forum. Sight Sciences’ management is scheduled to present on Tuesday, May 27, 2025, at 09:00 am PT / 12:00 pm ET. Interested parties may access a li ...

Core Insights - Sight Sciences, Inc. reported a revenue of $17.5 million for Q1 2025, a 9% decrease compared to the same period in the previous year, primarily due to lower Surgical Glaucoma revenue and fewer Dry Eye product sales [4][7][10] - The company reaffirmed its revenue guidance for the full year 2025, expecting approximately $70.0 million to $75.0 million, reflecting a 6% to 12% decline compared to 2024 [10] - Adjusted operating expenses guidance for 2025 has improved, now expected to be approximately $101.0 million to $105.0 million, representing a 0% to 4% increase compared to 2024 [11] Financial Performance - Surgical Glaucoma revenue was $17.1 million, down 6% year-over-year, attributed to a 10% decrease in account utilization due to Medicare restrictions [4][10] - Dry Eye revenue decreased to $0.4 million from $1.0 million in the prior year, mainly due to a focus on reimbursed market access for TearCare [4][10] - Gross profit for Q1 2025 was $15.1 million, with a gross margin of 86%, unchanged from the previous year [5][7] Operating Expenses - Total operating expenses were $29.0 million, a 7% decrease from $31.2 million in the prior year, driven by lower legal expenses [6][7] - Research and development expenses were $4.4 million, down 4% year-over-year, while selling, general, and administrative expenses decreased by 8% to $24.5 million [6][7] Net Loss and Cash Position - The net loss for Q1 2025 was $14.2 million, or $0.28 per share, an improvement from a net loss of $16.3 million, or $0.33 per share, in the same period last year [8][29] - As of March 31, 2025, cash and cash equivalents totaled $108.8 million, down from $120.4 million at the end of 2024 [9][26] Strategic Initiatives - The company is focused on building commercial momentum in minimally invasive glaucoma surgery (MIGS) and establishing equitable reimbursement for TearCare, alongside advancing its product pipeline [3][10] - The recent launch of OMNI Edge at the ASCRS Annual Meeting is part of the company's strategy to enhance its product offerings [7][10]

Core Viewpoint - Sight Sciences, Inc. is set to report its financial results for Q1 2025 on May 8, 2025, with a conference call scheduled to discuss the results [1] Company Overview - Sight Sciences is an eyecare technology company focused on developing innovative interventional solutions to improve patient care and address prevalent eye diseases [3] - The company's OMNI® Surgical System is designed for glaucoma surgery, indicated for reducing intraocular pressure in adult patients with primary open-angle glaucoma [3] - The SION® Surgical Instrument is a bladeless device used in ophthalmic procedures to excise trabecular meshwork [3] - The TearCare® System is cleared for localized heat therapy in adult patients with evaporative dry eye disease, addressing meibomian gland disease [3]

The Sustainability Report provides data for 2022 through 2024 on the Company’s environmental, social, and governance initiativesMENLO PARK, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that it has published its annual Sustainability Report, highlighting the Company’s sustainability activities, performance and res ...